Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Sonoma BioTherapeutics
company
About
Sonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $40M
- Industries
- Biotechnology,Life Science,Therapeutics
- Founded date
- Jan 1, 2020
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$335M
Sonoma BioTherapeutics has raised a total of
$335M
in funding over 2 rounds. Their latest funding was raised on
Aug 4, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 4, 2021 | Series B | $265M | 2 | — | — | Detail |
| Sep 30, 2020 | Series A | $30M | 3 | — | — | Detail |
| Feb 6, 2020 | Series A | $40M | 2 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
1
0
Sonoma BioTherapeutics has made 1 investments. Their most recent investment was on
Jan 11, 2022, when OneDios raised $1.20M.
Investors
Number of Lead Investors
Number of Investors
—
3
Sonoma BioTherapeutics is funded by 3 investors.
ARCH Venture Partners
and Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series B |
Lilly Asia Ventures
|
— | Series B |
Lyell Immunopharma
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
